PML is a rare but serious infection of the central nervous system (CNS). The Progressive Multifocal Leukoencephalopathy (PML) Consortium is a joint effort between Biogen Idec, Bristol-Myers Squibb, Elan Pharmaceuticals, Pfizer, MedImmune and Roche intended to enhance the understanding of and identify more effective methods of predicting, preventing and treating PML.
June 2013 Research Conference On June 19-20 the PML Consortium and New York Academy of Sciences will host a conference to address challenges and future directions of research relevant to PML mitigation, potential future cure, and risk stratification. Register now
